Renewing a Medical Cannabis Licence in Israel After the 2024 HMO Reform

Getting an Israeli medical cannabis licence is the part patients research. Keeping it is the part that actually determines whether treatment continues. Renewal in Israel is not a formality — it is a fresh clinical decision, on a clock, and since April 2024 it is a decision made by a different set of doctors than before. In the year after that change the national patient count fell for the first time in the programme's history, and the most likely reason is not that patients stopped needing cannabis. It is that renewals stopped going through.

The quick answer (2026):

• Renewal is not automatic and requires a fresh medical recommendation each time.
• Historically, licences ran in three-, six- or twelve-month cycles depending on the case.
• Since April 2024, most indications are renewed as an HMO prescription, not an Israel Medical Cannabis Unit (IMCU) licence.
• Chronic non-cancer pain and PTSD stayed with the IMCU — the two largest patient groups.
• Active licences fell 7.5% in the year after the reform — though the national count has since recovered to an all-time high of about 143,900 (May 2026).

This guide is general information about how the Israeli system works, not medical or legal advice. Renewal decisions belong to your treating physician; confirm current requirements with the Israeli Ministry of Health and your health fund.

Licence or prescription? What changed in April 2024

For three decades, Israeli medical cannabis ran on licences issued by the Health Ministry's medical cannabis unit — the IMCU, the body most patients still call by its Hebrew name, Yakar. A specialist submitted a form with the indication, prior treatments and medication history; an IMCU physician approved, denied or asked for more; and renewal repeated that process (Aviram, Journal of Cannabis Research, 2025).

A Health Ministry circular dated 31 March 2024, implemented from 1 April 2024, moved most of that work into the public health funds. Under the reform, HMO physicians trained and certified in the relevant specialty can prescribe cannabis directly, and can do so as a first-line option rather than a last resort (IM Cannabis, 1 April 2024).

The carve-out matters more than the headline. The reform "reallocated most medical indications to the authority of the Israeli HMOs for a prescription model… except for CNCP and PTSD, which remained under the IMCU authority" (Aviram, 2025). Those two indications accounted for roughly 80% of active licences by March 2025 — so most Israeli patients never moved to the new prescription track, while nearly everyone else did. Which queue you renew in depends entirely on your indication.

How often you have to renew

The published mechanics are less tidy than patients expect. Under the IMCU system, renewal was "required… every 3, 6, or 12 months, depending on several factors" (Aviram, 2025) — and the paper does not spell out which factors decide the interval. In practice the first year is the tightest: specialist clinics describe first-year licences running in three-month blocks with medical follow-up at least every three months, easing to roughly six-monthly review from the second year onward (Avisar Center).

Two practical points follow from that, and they are the ones patients most often get wrong.

• Start early. Renewal paperwork is generally expected around 45 working days before the licence expires — roughly two calendar months — together with a follow-up report justifying continued treatment and a consumption chart logging daily intake (Avisar Center). A chart that shows the monthly allowance running out early is also the evidence used to support a dose increase.
• A refusal can be appealed. Patients may submit an appeal form setting out why the reviewing physician erred (Avisar Center). It is a real route, not a formality, but it takes time you will not have if you started late.

No public source we could find states a fixed validity period for the newer HMO prescriptions, or a transition rule for licence-holders converting to them. The peer-reviewed review is explicit that the data does not exist: it notes only that "some transition lag is expected in large-scale bureaucratic processes" (Aviram, 2025). Treat any confident claim about HMO prescription duration with suspicion — including ours. Ask your health fund directly.

What the numbers show went wrong

Israel's patient count rose almost without interruption for a decade — from 3,097 active licences in April 2011 to a then-record 140,483 in January 2024, a 4,437% increase (Aviram, 2025). Then it reversed. By March 2025 the combined total of licences and prescriptions had fallen 7.5% to 129,900 — a level last seen in September 2023.

The review's proposed explanations are worth reading as a warning about renewal specifically. It points to "stricter HMO gatekeeping, non-renewal following irregularities investigations, and anticipatory behavior after reform announcements" (Aviram, 2025). On the second of those, it notes that several physicians had IMCU authorisation revoked over licences allegedly issued from private clinics rather than public healthcare settings — in one case a single doctor accounted for over 13,000 approvals — and that "once those licenses expired, many were likely not renewed by other physicians."

The disruption was uneven. Oncology-related approvals, which moved to the HMOs, collapsed from about 5% of licences in April 2024 to 0.4% by March 2025, with chemotherapy side-effects falling from 3% to 0.2%; epilepsy, colitis, palliative, autism and dementia approvals had been stable, then declined. PTSD, which stayed with the IMCU, kept climbing — from 16,478 patients to 18,074. Statistically, staying put was the safer place to be.

The decline looks temporary rather than structural. Israel recorded roughly 143,900 licence and prescription holders by May 2026, an all-time high above the pre-reform peak (Cannabis Magazine, 12 July 2026). The fuller trend is set out in our guide to Israel's medical cannabis patient numbers. But a recovered national total is cold comfort to an individual whose treatment lapsed for four months in 2024.

Renewal is also where the cost changes

Renewal resets the monthly bill, because the approved quantity is set on the licence. Until April 2019 patients paid a flat ₪370 a month regardless of quantity; from May 2019 Israel moved to market pricing through pharmacies at roughly ₪15–39 per gram — about ₪450–1,560 a month for a 30–40 gram allowance (Aviram, 2025). Approved doses have drifted upward since: the 20g and 30g bands roughly halved in share between 2021 and 2025 while the 50g and 60g bands more than doubled, and 40g is now the most common allowance. More grams means proportionally more out of pocket. See what medical cannabis costs in Israel.

One group is insulated: PTSD in Israel is largely combat-related, and many of those patients are treated under the Ministry of Defense's rehabilitation department with full reimbursement (Aviram, 2025).

Practical steps to avoid a gap

• Know which track you are on. Chronic non-cancer pain and PTSD renew through the IMCU; almost everything else renews as an HMO prescription. Confirm it rather than assuming.
• Diarise the deadline, not the expiry. Work back roughly 45 working days from expiry and treat that as the real date.
• Keep the consumption chart current. It is the primary evidence for both continuation and any dose change, and it cannot be reconstructed from memory.
• Confirm your prescriber is still authorised. The revocations described above stranded patients whose approving physician was no longer permitted to approve.
• Know your indication's standing. Some conditions — notably fibromyalgia and endometriosis — are not approved indications, which can mean rejection or long delays (Aviram, 2025). Our guide to qualifying conditions sets out where the lines fall.

The bottom line

Israel decentralised medical cannabis prescribing in April 2024 to widen access, and on a two-year view it worked — the patient count is at a record high. But the transition cost roughly ten thousand patients their place in the system for a period, and renewals were where they lost it. Nothing here is automatic: renewal is a repeat clinical decision, on a fixed clock, owned by whichever authority now holds your indication.

If you are approaching a first renewal, start with our guide to how to get a medical cannabis licence in Israel to see how the assessment works, and the Patient Access hub for the wider system. Note too that the programme is under active review — see is Israel banning smoked medical cannabis?.